Biblio

Author Title [ Type

] Year

Filters: Author is Ashida, Takashi [Clear All Filters]

Journal Article

Kamijo K, Shimomura Y, Shinohara A, Mizuno S, Kanaya M, Usui Y, Kim S-W, Ara T, Mizuno I, Kuriyama T, et al. Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation. Ann Hematol. 2023.

Shiratori S, Kurata M, Sugita J, Ota S, Kasahara S, Ishikawa J, Imada K, Onishi Y, Ishiyama K, Ashida T, et al. Graft-versus-host disease prophylaxis using low-dose antithymocyte globulin in peripheral blood stem cell transplantation - A matched-pair analysis. Transplant Cell Ther. 2021.

Ikeda K, Ohto H, Yamada-Fujiwara M, Okuyama Y, Fujiwara S-I, Muroi K, Mori T, Kasama K, Kanamori H, Iseki T, et al. Hematopoietic cell infusion-related adverse events in pediatric/small recipients in a prospective/multicenter study. Transfusion. 2020.

Haeno T, Rai S, Miyake Y, Inoue M, Fujimoto K, Fujii A, Iwata Y, Minamoto S, Taniguchi T, Kakutani H, et al. Long-term effectiveness and safety of high dose chemotherapy followed by autologous stem cell transplantation in daily practice in patients with diffuse large B-cell lymphoma. J Clin Exp Hematop. 2023.

Kurosawa S, Shimomura Y, Tachibana T, Ishiyama K, Ota S, Kobayashi T, Uchida N, Fukushima K, Ashida T, Matsuoka K-I, et al. Outcome of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic/myeloproliferative neoplasms-unclassifiable: a retrospective nationwide study of the Japan Society for Hematopoietic Cell Transplantation: Allo-HSCT for patient. Biol Blood Marrow Transplant. 2020.

Jo T, Yoshihara S, Okuyama Y, Fujii K, Henzan T, Kahata K, Yamazaki R, Takeda W, Umezawa Y, Fukushima K, et al. Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan. Br J Haematol. 2023.

Fuji S, Miyamura K, Kanda Y, Fukuda T, Kobayashi T, Ozawa Y, Iwato K, Uchida N, Eto T, Ashida T, et al. Short-term clinical outcomes after HLA 1-locus mismatched uPBSCT are similar to that after HLA-matched uPBSCT and uBMT. Int J Hematol. 2019.